SGCG
Gamma-sarcoglycan
Also known as: A4, DAGA4, DMDA, DMDA1, LGMD2C, MAM, MGC130048, SCARMD2, SCG3, SGCG_HUMAN, TYPE
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13326
- Gene
- SGCG
- Ensembl
- ENSG00000102683
- Chromosome
- 13
- Canonical length
- 291 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes gamma-sarcoglycan, one of several sarcolemmal transmembrane glycoproteins that interact with dystrophin. The dystrophin-glycoprotein complex (DGC) spans the sarcolemma and is comprised of dystrophin, syntrophin, alpha- and beta-dystroglycans and sarcoglycans. The DGC provides a structural link between the subsarcolemmal cytoskeleton and the extracellular matrix of muscle cells. Defects in the encoded protein can lead to early onset autosomal recessive muscular dystrophy, in particular limb-girdle muscular dystrophy, type 2C (LGMD2C). [provided by RefSeq, Oct 2008]
Canonical amino-acid sequenceUniProt
291 residues, UniProt reviewed canonical sequence.
>Q13326|SGCG
1 MVREQYTTAT EGICIERPEN QYVYKIGIYG WRKRCLYLFV LLLLIILVVN LALTIWILKV
61 MWFSPAGMGH LCVTKDGLRL EGESEFLFPL YAKEIHSRVD SSLLLQSTQN VTVNARNSEG
121 EVTGRLKVGP KMVEVQNQQF QINSNDGKPL FTVDEKEVVV GTDKLRVTGP EGALFEHSVE
181 TPLVRADPFQ DLRLESPTRS LSMDAPRGVH IQAHAGKIEA LSQMDILFHS SDGMLVLDAE
241 TVCLPKLVQG TWGPSGSSQS LYEICVCPDG KLYLSVAGVS TTCQEHNHIC LLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SGCG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.52
- Highest tissue expression
- 148 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 148 nTPM
- tongue: 135 nTPM
- heart muscle: 111 nTPM
- adipose tissue: 13 nTPM
- epididymis: 7.5 nTPM
- lung: 4.6 nTPM
Single-cell type
- myonuclei: 947 nCPM
- thymic myoid cells: 477 nCPM
- cardiomyocytes: 424 nCPM
- adipocytes: 179 nCPM
- fibro-adipogenic progenitors: 35 nCPM
- undifferentiated spermatogonia: 34 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 7.1 nTPM
- white matter: 3.7 nTPM
- pons: 3.4 nTPM
- medulla oblongata: 2.8 nTPM
- thalamus: 2.8 nTPM
- hippocampal formation: 2.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SGCG.
Disease | AllUniProt
Conditions SGCG is implicated in, by any mechanism.
- Muscular dystrophy, limb-girdle, autosomal recessive 5 (LGMDR5) MIM:253700
Disease | GeneticClinVar
113 pathogenic / likely-pathogenic of 613 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Autosomal recessive limb-girdle muscular dystrophy type 2C
- Autosomal recessive limb-girdle muscular dystrophy
- Inborn genetic diseases
- SGCG-related congenital myopathy
- SGCG-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.05
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.13
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SGCG in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SGCG as an antibody target. Whether an autoantibody or antibody against SGCG could matter depends on whether native SGCG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SGCG is annotated at the cell surface, where native SGCG is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SGCG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...